Filing Flows

Filing Flows › Alnylam Pharmaceuticals (ALNY) › Guidance & outlook

Alnylam Pharmaceuticals (ALNY) guidance and outlook

Alnylam Pharmaceuticals (ALNY) reaffirmed its guidance on Oct 29, 2026: Revenue $575M–$625M for FY2026.

Guidance and outlook

Alnylam Pharmaceuticals Revenue: guidance against what was reportedAlnylam Pharmaceuticals Revenue: guidance against what was reportedguided rangereported (above / within / below)FY2025$3.7BFY2026
Met or beat 1 of 1 guided periods. Grey: the last range guided before the figures came out; dot: the reported figure.

Latest guidance

MetricPeriodRangeChange
RevenueFY2026$575M–$625Mreaffirmed

From the earnings release filed Oct 29, 2026 (8-K on EDGAR).

Alnylam Pharmaceuticals' latest quarter

Alnylam Pharmaceuticals, Q3 2026: revenue $1.5B (+17% year over year), operating margin 23.7%, net earnings $2.2B, operating cash flow $341M. The chart follows the revenue to costs, profit and cash.

Questions

Did Alnylam Pharmaceuticals raise or lower its guidance?

Alnylam Pharmaceuticals (ALNY) reaffirmed its guidance on Oct 29, 2026: Revenue $575M–$625M for FY2026.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.